Rakuten Medical, Inc., is a biopharmaceutical company with offices in the USA, Japan, and Germany. We are focused on developing new cancer treatments based on the Photoimmunotherapy platform to treat a broad range of solid tumor types as a single agent and in combination with other immunomodulatory agents to generate long-lasting anticancer immunological responses. Rakuten Medical, Inc. is sponsoring a global Phase 3 multicenter clinical study to evaluate the efficacy and safety of ASP-1929 in patients with recurrent Head and Neck Cancer, as well as other Phase 2 studies in other cancer types.